SCHEMBL4477446

SCHEMBL4477446

COc1cc2c(Oc3ccc(NC(=O)NCCC(C)(C)C)c(Cl)c3)ccnc2cc1OCC(O)CN1CCOCC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR2 P21802 3/20 0.61
KDR P35968 14/20 0.51
PDGFRA P16234 5/20 0.51
FLT1 P17948 5/20 0.51
FLT4 P35916 5/20 0.51
RET P07949 3/20 0.51
KIT P10721 3/20 0.51
MET P08581 3/20 0.51
RIPK2 O43353 2/20 0.51
STK10 O94804 2/20 0.51
ABL1 P00519 2/20 0.51
PDGFRB P09619 2/20 0.51
BCR P11274 2/20 0.51
FGFR1 P11362 2/20 0.51
EPHB2 P29323 2/20 0.51
SLC6A3 Q01959 2/20 0.51
DDR1 Q08345 2/20 0.51
MAP4K2 Q12851 2/20 0.51
PTK6 Q13882 2/20 0.51
DDR2 Q16832 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13936836 1.00 FGFR2 (0.61) FGFR2KDRPDGFRAFLT1FLT4
SCHEMBL13936825 1.00 FGFR2 (0.61) FGFR2KDRPDGFRAFLT1FLT4
SCHEMBL4469140 0.94 FGFR2 (0.59) FGFR2KDRPDGFRAFLT1FLT4
SCHEMBL4470003 0.93 FGFR2 (0.60) FGFR2KDRPDGFRAFLT1FLT4
SCHEMBL4487517 0.93 FGFR2 (0.60) FGFR2KDRPDGFRAFLT1FLT4
SCHEMBL4483855 0.92 FGFR2 (0.61) FGFR2KDRPDGFRARETKIT
Hydrochloric Acid SCHEMBL4476357 0.92 FGFR2 (0.61) FGFR2KDRPDGFRARETKIT
SCHEMBL4475109 0.91 FGFR2 (0.54) FGFR2KDRPDGFRAFLT1FLT4
SCHEMBL4486537 0.90 FGFR2 (0.71) FGFR2KDRPDGFRAMETEGFR
SCHEMBL13936861 0.90 FGFR2 (0.71) FGFR2KDRPDGFRAMETEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US claimed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2005-03-03 US disclosed
EP-1447405-A1 QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING AUTO-PHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS KIRIN BEER KABUSHIKI KAISHA (JP) 2004-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors FGFR1, FGFR2, FGFR3 FGFR2 2/4885KDR 211/4885PDGFRA 372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.